Literature DB >> 33628799

Effects of miRNA-140 on the Growth and Clinical Prognosis of SMMC-7721 Hepatocellular Carcinoma Cell Line.

Cun-Qing Kong1, Xing-Cai Chen2, Guan-Hua Qiu3, Jing-Chen Liang3, Duo Wang3, Xin-Yu Liu4, Jun-Jie Liu3, Yao-Qi Han1, Xiao-Hui Fan1.   

Abstract

BACKGROUND: A growing number of studies have suggested that microRNAs exert an essential role in the development and occurrence of multiple tumours and act as crucial regulators in various biological processes. However, the expression and function of miRNA-140 in hepatocellular carcinoma (HCC) cells are not yet adequately identified and manifested.
METHODS: The expression of miRNA-140 was determined in HCC tissues and adjacent nontumour tissues by quantitative real-time polymerase chain reaction (qRT-PCR). Kaplan-Meier survival analysis and Cox regression analysis were performed to explore the correlation between miRNA-140 expression level and the survival rate of patients with HCC. Additionally, overexpression experiments were conducted to investigate the biological role of miRNA-140 in HCC cells. Bioinformatics was used to predict the related target genes and pathways of miRNA-140.
RESULTS: QRT-PCR results signified that the expression level of miRNA-140 in HCC was lower than that of adjacent normal tissues (P < 0.0001). Compared with the control group, the SMMC-7721 HCC cells in the miRNA-140 mimic group had a decrease in proliferation, migration, and invasion (P < 0.05), whereas those in the miRNA-140 inhibitor group had an increase in proliferation, migration, and invasion (P < 0.05). Cell cycle arrest occurred in the G0/1 phase. Prognosis analysis showed that the expression level of miRNA-140 was not related to the prognosis of HCC. Furthermore, the Kaplan-Meier test revealed that patients with lower miRNA-140 expression levels in liver cancer tissue had significantly shorter disease-free survival (DFS, P = 0.004) and overall survival (OS) times (P = 0.010) after hepatectomy. Cox regression analysis further indicated that miRNA-140 was an independent risk factor that may affect the DFS (P = 0.004) and OS times (P = 0.014) of patients after hepatectomy. Our results suggested that miRNA-140 might be a crucial regulator involved in the HCC progression and is thus considered a potential prognostic biomarker and therapeutic target for HCC.
Copyright © 2021 Cun-qing Kong et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33628799      PMCID: PMC7884124          DOI: 10.1155/2021/6638915

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


  40 in total

1.  A miRNA machinery component DDX20 controls NF-κB via microRNA-140 function.

Authors:  Akemi Takata; Motoyuki Otsuka; Takeshi Yoshikawa; Takahiro Kishikawa; Yotaro Kudo; Tadashi Goto; Haruhiko Yoshida; Kazuhiko Koike
Journal:  Biochem Biophys Res Commun       Date:  2012-03-16       Impact factor: 3.575

Review 2.  Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics.

Authors:  Ningning Yang; Nsikak R Ekanem; Clement A Sakyi; Sidhartha D Ray
Journal:  Adv Drug Deliv Rev       Date:  2014-11-06       Impact factor: 15.470

3.  Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

Authors:  L Bolondi; S Sofia; S Siringo; S Gaiani; A Casali; G Zironi; F Piscaglia; L Gramantieri; M Zanetti; M Sherman
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

4.  MicroRNA-140-5p inhibits cell proliferation and invasion by regulating VEGFA/MMP2 signaling in glioma.

Authors:  Yuan Hu; Yanyan Li; Chun Wu; Liang Zhou; Xiaoxiao Han; Qingyue Wang; Xueshun Xie; Youxin Zhou; Ziwei Du
Journal:  Tumour Biol       Date:  2017-04

Review 5.  The utility of serum exosomal microRNAs in hepatocellular carcinoma.

Authors:  Li Jun; Gu Yang; Liu Zhisu
Journal:  Biomed Pharmacother       Date:  2019-01-15       Impact factor: 6.529

Review 6.  [MicroRNAs as Biomarkers of Cardiovascular Diseases].

Authors:  V V Romakina; I V Zhirov; S N Nasonova; A V Zaseeva; A G Kochetov; O V Liang; S N Tereshchenko
Journal:  Kardiologiia       Date:  2018-01       Impact factor: 0.395

Review 7.  MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis.

Authors:  Qiaozhu Su; Virender Kumar; Neetu Sud; Ram I Mahato
Journal:  Adv Drug Deliv Rev       Date:  2018-01-31       Impact factor: 15.470

8.  Patterns and Trends of Liver Cancer Incidence Rates in Eastern and Southeastern Asian Countries (1983-2007) and Predictions to 2030.

Authors:  Jie Wu; Shigui Yang; Kaijin Xu; Cheng Ding; Yuqing Zhou; Xiaofang Fu; Yiping Li; Min Deng; Chencheng Wang; Xiaoxiao Liu; Lanjuan Li
Journal:  Gastroenterology       Date:  2018-03-14       Impact factor: 22.682

9.  MicroRNA-140-5p inhibits invasion and angiogenesis through targeting VEGF-A in breast cancer.

Authors:  Y Lu; T Qin; J Li; L Wang; Q Zhang; Z Jiang; J Mao
Journal:  Cancer Gene Ther       Date:  2017-07-28       Impact factor: 5.987

Review 10.  Circulating MicroRNAs in Cancer: Potential and Challenge.

Authors:  Mengying Cui; Hongdan Wang; Xiaoxiao Yao; Dan Zhang; Yingjun Xie; Ranji Cui; Xuewen Zhang
Journal:  Front Genet       Date:  2019-07-18       Impact factor: 4.599

View more
  2 in total

1.  Comprehensive analysis of GSEC/miR-101-3p/SNX16/PAPOLG axis in hepatocellular carcinoma.

Authors:  Shangshang Hu; Jinyan Zhang; Guoqing Guo; Li Zhang; Jing Dai; Yu Gao
Journal:  PLoS One       Date:  2022-04-28       Impact factor: 3.240

Review 2.  Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021.

Authors:  Chunyan Zhang; Caifang Sun; Yabin Zhao; Qiwen Wang; Jianlin Guo; Bingyu Ye; Guoying Yu
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.